TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Monday

TScan Therapeutics (NASDAQ:TCRX) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $1.31 million for the quarter.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. The company had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.62 million. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Price Performance

Shares of NASDAQ TCRX opened at $1.64 on Friday. TScan Therapeutics has a 1 year low of $1.02 and a 1 year high of $6.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.55 and a quick ratio of 8.55. The company’s 50-day moving average is $1.67 and its 200 day moving average is $1.69. The stock has a market capitalization of $92.81 million, a P/E ratio of -1.50 and a beta of 0.99.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. HC Wainwright dropped their price objective on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Wedbush reissued an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, May 6th. Finally, Wall Street Zen raised shares of TScan Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 12th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.80.

Insider Buying and Selling

In other news, major shareholder Lynx1 Capital Management Lp bought 1,200,000 shares of the firm’s stock in a transaction on Tuesday, May 20th. The stock was acquired at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the completion of the acquisition, the insider owned 7,946,141 shares of the company’s stock, valued at approximately $9,535,369.20. This represents a 17.79% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.35% of the stock is owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TScan Therapeutics stock. Goldman Sachs Group Inc. grew its position in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 6.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 170,349 shares of the company’s stock after buying an additional 9,676 shares during the period. Goldman Sachs Group Inc. owned approximately 0.30% of TScan Therapeutics worth $235,000 as of its most recent SEC filing. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.